Resmed Inc. (NYSE:RMD) shares traded 0.06% higher at $152.61 on Wall Street last session.
In accordance with the data, 23 analysts cover Resmed Inc. (NYSE:RMD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $267.18 and a low of $158.00, we find $190.52. Given the previous closing price of $152.52, this indicates a potential upside of 24.91 percent. RMD stock price is now 5.29% away from the 50-day moving average and -21.15% away from the 200-day moving average. The market capitalization of the company currently stands at $22.45B.
It has been rated a hold by 5 analysts and a buy by 14. Brokers who have rated the stock have averaged $190.74 as their price target over the next twelve months.
With the price target reduced from $180 to $169, Morgan Stanley Upgraded its rating from Equal-Weight to Overweight for Resmed Inc. (NYSE: RMD).
In other news, Farrell Michael J., Chief Executive Officer sold 5,678 shares of the company’s stock on Nov 15. The stock was sold for $863,281 at an average price of $152.04. Upon completion of the transaction, the Chief Executive Officer now directly owns 440,986 shares in the company, valued at $67.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 01, Global General Counsel Rider Michael J sold 25 shares of the business’s stock. A total of $3,585 was realized by selling the stock at an average price of $143.42. This leaves the insider owning 7,358 shares of the company worth $1.12 million. Insiders disposed of 188,461 shares of company stock worth roughly $28.76 million over the past 1 year. A total of 0.81% of the company’s stock is owned by insiders.
Resmed Inc. (NYSE: RMD) opened at $153.99 on Wednesday. During the past 12 months, Resmed Inc. has had a low of $132.24 and a high of $243.52. As of last week, the company has a debt-to-equity ratio of 0.35, a current ratio of 2.99, and a quick ratio of 1.75. According to the stock market information, the enterprise value for the company is $23.73B, which is based on a 24.83 price-to-earnings ratio, a 2.14 price-to-earnings-growth ratio, and a beta of 0.53. The fifty day moving average price for RMD is $144.94 and a two-hundred day moving average price translates $193.54 for the stock.
The latest earnings results from Resmed Inc. (NYSE: RMD) was released for Sep, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at $1.64, beating analysts’ expectations of $1.62 by 0.02. This compares to $1.43 EPS in the same period last year. The net profit margin was 20.72% and return on equity was 23.60% for RMD. The company reported revenue of $1.1 billion for the quarter, compared to $950.29 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 16.0 percent. For the current quarter, analysts expect RMD to generate $1.15B in revenue.
Resmed Inc.(RMD) Company Profile
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN’s software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
